Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cogent Biosciences, Inc. COGT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$48.13
+31.9%

Cogent Biosciences, Inc. (COGT) is a Biotechnology company in the Healthcare sector, currently trading at $36.49. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is COGT = $48 (+31.9% upside).

Valuation: COGT trades at a trailing Price-to-Earnings (P/E) of -7.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.

Net income is $329M (loss), growing at -35.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $253M against $636M equity (Debt-to-Equity (D/E) ratio 0.4, conservative). Current ratio is 14.23 (strong liquidity). Debt-to-assets is 27%. Total assets: $938M.

Analyst outlook: 10 / 12 analysts rate COGT as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 79/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$48.13
▲ 31.9% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Cogent Biosciences, Inc., the average price target is $48.13, with a high forecast of $60.00, and a low forecast of $35.00.
Highest Price Target
$60.00
Average Price Target
$48.13
Lowest Price Target
$35.00

COGT SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 79/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — COGT

✓
VALUE Pass
79/100
COGT trades at a trailing Price-to-Earnings (P/E) of -7.6 (S&P 500 average ~25). Forward PEG 0.11 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.35. Analyst consensus target is $48, implying +31.5% from the current price $36. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
COGT: +0%/yr revenue is, -35.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet COGT: Debt-to-Equity (D/E) ratio 0.4 (conservative), Current ratio is 14.23 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
COGT: Gross margin is 0% (+0 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 10 / 12 analysts rate COGT as buy (83%). Analyst consensus target is $48 (+31.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.72-43.73
Volume2.14M
Avg Volume (30D)2.15M
Market Cap$5.92B
Beta (1Y)0.47
Share Statistics
EPS (TTM)-2.55
Shares Outstanding$67.6M
IPO Date2018-03-29
Employees205
CEOAndrew R. Robbins
Financial Highlights & Ratios
Gross Profit$-4.62M
EBITDA$-328.74M
Net Income$-328.94M
Operating Income$-333.36M
Total Cash$900.77M
Total Debt$253.15M
Net Debt$-58.86M
Total Assets$937.61M
Price / Earnings (P/E)-14.3
Analyst Forecast
1Y Price Target$50.00
Target High$60.00
Target Low$35.00
Upside+37.0%
Rating ConsensusBuy
Analysts Covering12
Buy 83% Hold 17% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS19240Q2012

Price Chart

Track all markets on TradingView
COGT
Cogent Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
3.72 52WK RANGE 43.73

People Also View

VRNA
VRNA
Verona Pharma plc
$106.91
+0.11%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 KNSA
KNSA
Kiniksa Pharmaceuticals, Ltd.
$46.92
-0.80%
 IDYA
IDYA
IDEAYA Biosciences, Inc.
$32.35
-1.43%
 SNDX
SNDX
Syndax Pharmaceuticals, Inc.
$24.43
+0.74%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message